Literature DB >> 8702857

Ubiquitination of protein kinase C-alpha and degradation by the proteasome.

H W Lee1, L Smith, G R Pettit, A Vinitsky, J B Smith.   

Abstract

Bryostatins and phorbol esters acutely activate and subsequently down-regulate protein kinase C (PKC) by inducing its proteolysis via an unknown pathway. Here we show that treatment of renal epithelial cells with bryostatin 1 (Bryo) produced novel PKC-alpha species, which were larger than the native protein (80 kDa). The >80 kDa PKC-alpha species contained Ubi as indicated by immunostaining and accumulated in the presence of lactacystin, a selective inhibitor of proteolysis by the proteasome. In vitro experiments with 125I-ubiquitin and membranes from Bryo-treated cells showed that PKC-alpha became ubiquitinated by a reaction that depended on ATP and a cytosolic fraction. Lactacystin or a peptidyl aldehyde, Bz-Gly-Leu-Ala-leucinal, which inhibits certain proteinase activities of the proteasome, inhibited Bryo-evoked disappearance of PKC-alpha protein from the cells. Lacta preserved Bryo-induced 32P-labeled PKC-alpha indicating that the proteasome inhibitor spared activated enzyme from down-regulation in vivo. These findings show that Bryo induces the degradation of PKC-alpha by the ubiquitin-proteasome complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702857

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis.

Authors:  B L Webb; S J Hirst; M A Giembycz
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 2.  The life and death of protein kinase C.

Authors:  Christine M Gould; Alexandra C Newton
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

3.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

Review 4.  Atypical protein kinase Cι as a human oncogene and therapeutic target.

Authors:  Peter J Parker; Verline Justilien; Philippe Riou; Mark Linch; Alan P Fields
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

5.  Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes.

Authors:  G Hansra; P Garcia-Paramio; C Prevostel; R D Whelan; F Bornancin; P J Parker
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

6.  Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord.

Authors:  Jing-Dun Xie; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2017-06-27       Impact factor: 5.250

7.  Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor.

Authors:  R Govers; P van Kerkhof; A L Schwartz; G J Strous
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

Review 8.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

9.  A protein kinase C/protein kinase D pathway protects LNCaP prostate cancer cells from phorbol ester-induced apoptosis by promoting ERK1/2 and NF-{kappa}B activities.

Authors:  Jun Chen; Karthik V Giridhar; Liyong Zhang; Shuping Xu; Q Jane Wang
Journal:  Carcinogenesis       Date:  2011-06-10       Impact factor: 4.944

10.  Caspase processing activates atypical protein kinase C zeta by relieving autoinhibition and destabilizes the protein.

Authors:  Lucinda Smith; Zhi Wang; Jeffrey B Smith
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.